Showing 1 - 3 results of 3 for search 'J. Potluri', query time: 0.02s Refine Results
  1. 1
    P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY

    P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY by V. Pullarkat, A. Cruz-Chacon, S. Gangatharan, A. Melnyk, G. A. Palumbo, M. Bellini, S. K. Tantravahi, Q. Qin, J. Potluri, P. Vachhani

    Published 2022-06-01
    Get full text
    Article
  2. 2
    S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY

    S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY by F. Passamonti, J. Foran, A. Tandra, V. De Stefano, M. Laura Fox, A. Mattour, M. F. McMullin, A. C. Perkins, G. Rodriguez-Macías, H. Sibai, Q. Qin, J. Potluri, J. How

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P510: THE IMPACT OF POST-REMISSION GRANULOCYTE COLONY-STIMULATING FACTOR USE IN THE PHASE 3 STUDIES OF VENETOCLAX COMBINATION TREATMENTS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

    P510: THE IMPACT OF POST-REMISSION GRANULOCYTE COLONY-STIMULATING FACTOR USE IN THE PHASE 3 STUDIES OF VENETOCLAX COMBINATION TREATMENTS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYEL... by C. DiNardo, K. Pratz, P. Panayiotidis, X. Wei, V. Vorobyev, Á. Illés, I. Kim, V. Ivanov, G. Ku, C. L. Miller, M. Zhang, F. Tatsch, J. Potluri, X. Schmidt, C. Recher

    Published 2022-06-01
    Get full text
    Article

Search Tools: